Summary of Qualifications (CV)

Jason G. Bankert, DO
Altoona Center for Clinical Research
175 Meadowbrook Lane
Duncansville, PA 16635

EDUCATION:

July 2013 - May 2016
Lake Erie College of Osteopathic Medicine, Erie, PA

August 2007 – May 2013
Pennsylvania State University, University Park, PA

TRAINING:

July 2019 - July 2021
Rheumatology Fellowship
Geisinger Commonwealth School of Medicine, Danville, PA

July 2017 – July 2019
General Internal Medicine Residency
Geisinger Commonwealth School of Medicine, Danville, PA

July 2016 – July 2017
Internship
Geisinger Commonwealth School of Medicine, Danville, PA

SUMMARY OF CURRENT WORK EXPERIENCE:

August 2021 to Present
Altoona Center for Clinical Research
Altoona Arthritis and Osteoporosis Center
175 Meadowbrook Lane, Duncansville, PA 16635.

Clinical Trials –SubInvestigator on clinical trials consisting of low back pain, osteoarthritis, osteoporosis, rheumatoid arthritis, ankylosing spondylitis, diabetic neuropathy, chronic pain, fibromyalgia, psoriatic arthritis, polymyositis, dermatomyositis, and lupus.

CURRENT LICENSURE(S): Pennsylvania License OS021061

Jason G. Bankert, D.O.

Training
July 2019-
Rheumatology Fellowship, Geisinger Commonwealth School of Medicine – Danville, PA
-Musculoskeletal Ultrasound training, projected RhMSUS certification, May 2021
-Bone densitometry training, projected Clinical Densitometrist, May 2021
-Quality Improvement training
July 2017 – June 2019
General Internal Medicine Residency, Geisinger Commonwealth School of Medicine – Danville, PA
July 2016-Jult 2017
Internship, Geisinger Commonwealth School of Medicine – Danville, PA

Education
July 2013-May 2016
Lake Erie College of Osteopathic Medicine – Erie, PA

August 2007-May 2013
Pennsylvania State University – University Park, PA

Licensures/Certifications
Pennsylvania License, Training, License # OT017003, July 2019
American Board of Internal Medicine Certification, November 2019
BLS, July 2020
ACLS, January 2020

Honors/Awards
West Allegheny Physicians Association Scholarship
LECOM Academic Excellence Award
Penn State Schreyer Honors Scholar
Graduation with distinction from Penn State College of Agricultural Sciences
Alpha Lambda Delta National Academic Honor Society

Presentations
Bankert, J. (2019) "Besides Cytoxan and Rituxan, what other therapeutic options exist for AAV?" Geisinger Medical Center Visiting Professor CME Conference
Bankert, J. (2019) "A case of splenic sarcoidosis." Poster presentation at the Pennsylvania Rheumatology Society Annual Meeting
Bankert, J. (2018) "Platelet-rich Plasma for Knee OA." Geisinger Medical Center Osteopathic Grand Rounds presentation
Bankert, J. (2018) "A case of multi-system sarcoidosis initially presenting in the prostate." Poster presentation at the Pennsylvania Rheumatology Society Annual Meeting and oral presentation at the Geisinger Medical Center Resident and Fellow Research Day
Bankert, J. (2018) Geisinger Medical Center Morbidity and Mortality Conference

Research/Quality Improvement
"Improving Value Concordant Care in Rheumatoid Arthritis" 2019-Present
-Quality improvement project with aim to improve Treat-to-Target and value concordant care in our rheumatology department.
-Virtual presentation at ACR Convergence 2020

"Axial Spondyloarthritis (AxSpA) Patient Identification Quality Improvement Protocol" 2020-Present
-Quality improvement project evaluating the feasibility of different patient identification and screening processes in patients with suspected axial spondyloarthropathy to improve earlier identification, specialty referrals and earlier diagnosis of axial spondyloarthropathy.

"Epidemiologic and Geographic Evaluation of ANCA-Associated Vasculitis (AAV) at a Rural Academic Health Center Utilizing an Electronic Health Record (EHR)" 2018-Present
-Retrospective observation study evaluating the prevalence of ANCA vasculitis in a rural population compared to national average, and geographic distribution of cases.
-ACR 2020 abstract submission

Elleder, D., Kim, O., Padhi, A., Bankert, J.G., Simeonov, I., Wittekindt, N., Motameny, S. & Poss, M. "Polymorphic integrations of an endogenous gammaretrovirus in the mule deer population. Journal of Virology. 2012, Mar; 86(5): 2787-2796. Cited in PubMed; PMID: PMC3302240. Pub Status: Published.

Organizations/Societies
2019 – Present
American College of Rheumatology
2018 – Present
Pennsylvania Rheumatology Society
2013-2014
Christian Medical Dental Association (CMDA), Vice-President

Hobbies/Interests
Bible study
Running
Kayaking

Clinical Trial Experience:

AbbVie Protocol M20-370: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment

AbbVie: Protocol M20-466: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs)

Acadia ACP-044-005
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee

Aclaris ATI-450-RA-202: A Phase 2b, Randomized, Multicenter, Double-blind, Parallel Group, Placebo Controlled, Dose Ranging Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA) who have had an Inadequate Response to MTX Alone

Aptinyx NYX-2925-2008
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NYX-2925 in Subjects with Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

Arthrosi A Phase 2b, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of AR882 versus Placebo in Gout Patients
Protocol #AR882-202

Avalo AVTX-002-RA-201: A Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of AVTX-002 in Combination with Methotrexate in Patients with Moderate to Severe Rheumatoid Arthritis who are Biologic Experienced

BMS A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis (PsA) who are Naive to Biologic Disease Modifying Anti-rheumatic Drugs or had Previously Received TNFa Inhibitor Treatment-IM011-055

BMS A Randomized, Head-to-head, Single-blind Study to Compare the Response to Treatment with Subcutaneous Abatacept vs Adalimumab, on Background Methotrexate, in Adults with Early, Seropositive Rheumatoid Arthritis Who Have "Shared Epitope" HLA Class II Risk Alleles and Have an Inadequate Response to Methotrexate-IM101-863

Celgene/BMS Protocol Number: CC-99677-AS-001
Protocol Title: A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-99677 IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS

Eliem ETX-018810-201: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX-018810 in Subjects with Lumbosacral Radicular Pain

EQRX: EQ121-010: A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered EQ121 Following Single and Multiple Doses in Healthy Adult Volunteers and Adults with Rheumatoid Arthritis

Gilead GS-US-561-5898: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 on Background Therapy with Conventional Synthetic Disease-modifying Antirheumatic Drug(s) (csDMARDs) in Participants with Active Rheumatoid Arthritis who have an Inadequate Response to Biologic DMARD(s) Treatment

Horizon HZNP-KRY-407: A Phase 4, Multicenter, Open-label, Efficacy and Safety Trial of Pegloticase and Methotrexate Co-administered in Patients with Uncontrolled Gout who have Previously Received Pegloticase Monotherapy but did not Maintain a Serum Uric Acid Response

Horizon A Phase 4, Open-Label, Multicenter, Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Trial of Intravenous KRYSTEXXA® (pegloticase) Administered Every 4 Weeks with Co-Administration of Weekly Doses of Methotrexate in Patients with Uncontrolled Refractory Gout (FORWARD Open-Label [OL] Trial)

Inmagine ABY-035-204
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of ABY-035 in the Treatment of Subjects with Ankylosing Spondylitis

Janssen A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS)
Protocol 80202135SJS2001
IND#153834

Janssen Protocol CNTO1959PSA3004: A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants with Active Psoriatic Arthritis.

Kangpu Protocol KPG-818-SLE: A Phase 1b/2a Multicenter Study to Assess the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of KPG-818 in Patients with Systemic Lupus Erythematosus; IND 136549

Kiniksa KPL-404-C211 - A Phase 2, Multicenter, Randomized, Double-blind, Placebo controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Subjects with Moderate to Severe, Active Rheumatoid Arthritis with Inadequate Response or Intolerance to at Least one Biologic Disease-modifying Anti rheumatic Drug or Janus Kinase Inhibitor.

Lilly I4V-MC-JADA A Randomized, Controlled, Pragmatic Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis

Lilly Branch Baricitinib (LY3009104) Protocol I4V-MC-JAJD
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis

Merck MK-0616-008: A Phase 2B, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Participants with Hypercholesterolemia

Navidea NAV3-35: "Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging with Tc 99m Tilmanocept."

Novartis Pharmaceuticals trial entitled: An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
Protocol No.:CAIN457A02001B

Novartis Pharmaceuticals trial entitled: A randomized, double-blind, placebo-controlled, parallel group, phase III multicenter study of intravenous secukinumab to compare efficacy at 16 weeks with placebo and to assess safety and tolerability up to 52 weeks in subjects with active Ankylosing Spondylitis or non-radiographic axial SpondyloArthritis
Protocol No.: CAIN457P12301

Paradigm A 2-stage, Adaptive, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate Dose and Treatment Effect of Pentosan Polysulfate Sodium Compared with Placebo in Participants with Knee Osteoarthritis Pain
PARA_OA_002

Pfizer A PHASE 2B, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 (BNT162b2) IN ADULTS WITH STABLE RHEUMATOID ARTHRITIS RECEIVING BACKGROUND TOFACITINIB OR BACKGROUND TNF INHIBITORS- Protocol C4591018
Site # 1007

Servier Study Code: CL2-95011-001. Test drug code: S95011.
Study official title: A phase IIa efficacy and safety trial with intravenous S95011 in primary Sjögren's Syndrome patients. An international, multicentre, randomised, double-blind, placebo-controlled study
Study public title: Efficacy and safety of S95011 in primary Sjögren's Syndrome patients

Techfields A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, 22-WEEK AND 30-WEEK OPEN LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF X0002 SPRAY IN RELIEF OF THE PAIN FOR SUBJECTS WITH OSTEOARTHRITIS OF THE KNEE
TF-X0002-31

TEVA A Randomized, Double-Blind, Multinational, Multicenter Study to Compare Efficacy, Safety, and Immunogenicity of TVB-009P and Denosumab (PROLIA®) in Patients with Postmenopausal Osteoporosis
Protocol Number: TVB009-IMB-30085 Novum Study Number: 72036002 IND Number: 137313

UCB A multicenter, open-label extension study to assess the long-term Safety and Tolerability of Dapirolizumab Pegol treatment in study participants with systemic Lupus Erythematosus. - SL0046